FOGHORN THERAPEUTICS INC. - COMMON STOCK

Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference

05 مايو 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

01 مايو 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update

28 أبريل 2025 16:05:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting

15 أبريل 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting

25 مارس 2025 16:35:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook

06 مارس 2025 16:05:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

25 فبراير 2025 07:00:01 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025

13 يناير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities

16 ديسمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

12 نوفمبر 2024 07:54:32 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update

04 نوفمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors

10 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate in the BMO Oncology Summit

01 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer

03 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September

28 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update

08 أغسطس 2024 07:00:01 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June

28 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline

22 مايو 2024 18:21:05 بحسب Nasdaq GlobeNewswire

Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants

20 مايو 2024 07:58:16 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update

06 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire